New Indication for Abbott's Humira - Analyst Blog

By
A A A

Abbott Labs ( ABT ) recently announced that it has received approval for an additional indication of Humira (adalimumab) from the US Food and Drug Administration (FDA). The FDA approved Humira for inducing and sustaining clinical remission in adult patients suffering from moderately to severely active ulcerative colitis when certain other medicines have not worked sufficiently.

Approval for this indication comes a few weeks after Abbott Labs gained approval from the European Commission (EC) for Humira for the treatment of moderately active Crohn's disease in adult patients who have responded inadequately to conventional therapy. Earlier this year, Humira had gained EC approval for the treatment of adults with severe axial spondyloarthritis (axSpA) who have no X-ray evidence of structural damage.

We note that Abbott Labs gained EC approval for Humira in April 2012 for treating adults suffering from moderately to severely active ulcerative colitis. The product gained approval for use in patients who did not respond satisfactorily to standard drugs for ulcerative colitis treatment.

Humira is a key product in Abbott Labs' pharmaceutical products portfolio. Humira is approved for several indications including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, psoriasis, juvenile idiopathic arthritis, and Crohn's disease. Humira sales increased 21.1% to $7.9 billion in 2011. Growing awareness, favorable clinical data, additional indications and expansion into new markets like China and Japan should help the product to continue contributing significantly to the top-line.

Other players in the anti-inflammatory market include Pfizer / Amgen's ( PFE / AMGN ) Enbrel, Johnson & Johnson / Merck' s ( JNJ / MRK ) Remicade and Simponi.

We currently have a Neutral recommendation on Abbott Labs, which carries a Zacks #3 Rank (short-term 'Hold' rating).


 
ABBOTT LABS (ABT): Free Stock Analysis Report
 
AMGEN INC (AMGN): Free Stock Analysis Report
 
JOHNSON & JOHNS (JNJ): Free Stock Analysis Report
 
MERCK & CO INC (MRK): Free Stock Analysis Report
 
PFIZER INC (PFE): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: ABT , AMGN , EC , JNJ , MRK

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Stocks

Referenced

Most Active by Volume

61,354,178
  • $10.59 ▲ 13.26%
57,732,182
  • $16.27 ▲ 1.12%
51,991,548
  • $103.30 ▲ 0.78%
48,129,834
  • $20.65 ▲ 5.52%
41,623,916
  • $12.63 ▲ 8.13%
34,295,241
  • $76.68 ▲ 2.49%
31,519,079
  • $34.57 ▼ 1.00%
28,847,879
  • $3.64 ▲ 0.28%
As of 9/2/2014, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com